Publications describing the use of
Quality of Life Measurement in Dermatology

1. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use. Clinical and Experimental Dermatology 1994; 19: 210-216.

2. Kurwa H, Finlay AY. Dermatology inpatient management greatly improves life quality. British Journal of Dermatology 1995; 133: 575-578.

3. Finlay AY. Measures of the effect of severe atopic eczema on quality of life. Journal of the European Academy of Dermatology and Venereology, 1996; 7: 149-154.

4. Blackford S, Roberts DL, Salek MS, Finlay AY. Basal cell carcinomas cause little handicap. Quality of Life Research 1996; 5: 191-194.

5. Nichol MB, Margoilies JE, Lippa E, Rowe M, Quell J. The application of multiple quality of life instruments in individuals with mild-to-moderate psoriasis. Pharmacoeconomics 1996; 10: 644-653.

6. Kent G, Al-Abadie M. Factors affecting responses on Dermatology Life Quality Index items among vitiligo sufferers. Clinical and Experimental Dermatology 1996; 21: 330-333.

7. Harris A, Burge SM, Dykes PJ, Finlay AY. Handicap in Darier's disease and Hailey-Hailey disease. British Journal of Dermatology 1996; 135: 959-963.

8. Piletta P A, Wirth S et al. Circulating skin-homing T cells in atopic dermatitis. Arch Dermatol 1996; 132: 1171-1176.

9. Jemec GB, Wulf HC. Patient-physician consensus on quality of life in dermatology. Clinical and Experimental Dermatology 1996; 21: 177-179.

10. Blackford S, Finlay AY, Roberts DL. Quality of life in Behcets' syndrome: 335 patients surveyed. British Journal of Dermatology 1997; 136: 293.

11. Herd RM, Tidman MJ, Ruta DA, Hunter JAA. Measurement of quality of life in atopic dermatitis: correlation and validation of two different methods. British Journal of Dermatology 1997; 136: 502-507.

12. Williamson D, Gonzalez M, Finlay AY. Quality of life in patients with hair loss. British Journal of Dermatology 1997; 137 (Suppl 50): 47.

13. Newton JN, Mallon E, Klassen A, Ryan TJ, Finlay A. The effectiveness of acne treatment: an assessment by patients of the outcome of therapy. British Journal of Dermatology 1997; 137: 563-567.

14. Finlay AY. Quality of life measurement in dermatology: a practical guide. British Journal of Dermatology 1997; 136: 305-314.

15. Finlay AY. Dermatology Life Quality Index: initial experience of a simple practical measure. Chapter in: Care management of skin disease: Life quality and economic impact. Editors: R Rajagopalan, E.F. Sherertz, R.T. Anderson. Marcel Dekker, New York 1998 p85-94.

16. Harlow D, Poyner T, Finlay AY, Dykes PJ. High impairment of quality of life of adults with skin diseases in primary care. British Journal of Dermatology 1998; 139 (Suppl 51): 15.

17. Finlay AY, Coles EC, Lewis-Jones MS, Blackford S, Holt PJA, Howard A, Knight AG, Lanigan SW, Logan RA, Long CC, Marks R, Motley RJ, Roberts DLL, Statham BN, Wilkins J. Quality of life improves after seeing a dermatologist. British Journal of Dermatology 1998; 139 (Suppl 51): 15.

18. Poon E, Greaves MW, Kobza-Black A. Extent of disability in different urticarial disorders. British Journal of Dermatology 1998; 139 (Suppl 51): 15.

19. de Tiedra AG, Mercadal J, Badia X, Mascaró JM, Lozano R. A method to select an instrument for measurement of HR-QOL for cross-cultural adaptation applied to dermatology. Pharmacoeconomics 1998; 14: 405-422.

20. de Tiedra AG, Mercadal J, Badia X, Mascaró JM, Herdmann M, Lozano R. Adaptación transcultural al Espańol del cuestionario Dermatology Life Quality Index (DLQI): el Índice de Calidad de Vida en Dermatologia. Actas Dermo-Sifiliograficas 1998; 89: 692-700.

21. Grosshans E et al. Evaluation of clinical efficacy and safety of adapelene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. British Journal of Dermatology 1998; 139 (Suppl 52): 26-33.

22. Ruta D, Allen S, Herd R, Tidman M. The patient generated index: a new approach to quality of life measurement in psoriasis. Quality of Life Research 1998; 7: 657.

23. Iliev D, Furrer L, Elsner P. Estimating the quality of life of dermatologic patients. Hautarzt 1998; 49: 453-456.

24. Finlay AY. Quality of life assessments in dermatology. Seminars in Cutaneous Medicine and Surgery 1998; 17: 291-296.

25. Bagel J, Garland W T, Breneman D et al. Administration of DAB 389 IL-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicentre trial. J Am Acad of Dermatol 1998; 38: 938-944.

26. Papadopoulos L et al. Coping with the disfiguring effects of vitiligo. British Journal of Medical Psycholog 1999; 72: 385-396.

27. Linnet J, Jemec GBE. An assessment of anxiety and dermatology life quality in patients with atopic dermatitis. British Journal of Dermatology 1999; 140: 268-272.

28. Poon E, Seed PT, Greaves MW, Kobza-Black A. The extent and nature of disability in different urticarial conditions. British Journal of Dermatology 1999; 140: 667-671.

29. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. British Journal of Dermatology 1999; 140: 672-676.

30. Ayyalaraju RS, Finlay AY, Kirsner RS, Trent JT, Kerdel FA. Dermatology Inpatient Services: A UK/USA Comparative Study. British Journal of Dermatology 1999; 141 (Suppl 55): 79-80.

31. Mufleh L, Gonzalez M, Judodihardjo H, Finlay AY. Compliance is high in patients taking oral Isotretinoin for acne. British Journal of Dermatology 1999; 141 (Suppl 55): 87.

32. Zaghloul S, Gonzalez M, Judodihardjo H, Finlay AY. In psoriasis, the greater the disability, the poorer the topical treatment compliance. British Journal of Dermatology 1999; 141 (Suppl 55): 48.

33. Kochergin NG, Ivandv OL, Burova EP. Quality of Life and Long Term Cyclosporine, a Treatment in Psoriasis. Journal of the European Academy of Dermatology and Venereology 1999; 12 (Suppl 2): S333.

34. Badia X, Mascaro JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensibility to change of the DLQI. British Journal of Dermatology 1999; 141: 698-702.

35. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. British Journal of Dermatology 1999; 141: 1067-1075.

36. Augustin M, Zschocke I, Lange S, Seidenglanz K, Amon U. Quality of life in skin diseases: methodological and practical comparison of different quality of life questionnaires in psoriasis and atopic dermatitis. Hautarzt 1999; 50: 715-22.

37. Giess R, Naumann M, Werne E, Riemann R, Beck M, Puls I, Reiners C, Toyka K V. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000; 69: 121-123.

38. Shum RW, Lawton S, Williams HC, Docherty G, Jones J. The British Association of Dermatologists audit of atopic eczema management in secondary care. Phase 3: audit of service outcome. British Journal of Dermatology 2000; 142: 721-727.

39. Ayyalaraju R S, Finlay A Y, Dykes P J, Trent J T, Kerdel F A, Kirsner R S. Dermatology in-patients services: A UK/USA comparative study. J Invest Dermatol 2000; 114: 886.

40. Rzany B J, Partscht K, Kippes W, Ettrich A, Baima B et al. Quality of life in patients with Bullous pemphigoid. J Invest Dermatol 2000; 114: 887.

41. Czech W, Brautigam M, Weidinger G, Schopt F. A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol 2000; 42: 653-659.

42. Hutchings CV, Shum KW, Gawkrodger DJG. Occupational contact dermatitis has an appreciable impact on quality of life. British Journal of Dermatology 2000; 143 (Suppl 57): 27.

43. Helbing I, Muston HL, Ferguson JE. Audit of admissions to dermatology beds in the north-west. British Journal of Dermatology 2000; 143 (Suppl 57): 42.

44. Lanigan SW, Kwan CK, Dykes PJ, Gonzalez MG. Quality of life studies in hirsute women receiving ruby laser treatment. British Journal of Dermatology 2000; 143 (Suppl 57): 50

45. Zachariae R, Zachariae C. Ibsen H, Mortensen J T, Wulf H C. Dermatology life quality index: data from Danish inpatients and outpatients. Acta Derm Venereol 2000; 80: 272-276.

46. Kernick D, Cox A, Powell R, Reinhold D, Sawkins J, Warin A. A cost consequence study of the impact of a dermatology-trained practice nurse on the quality of life of primary care patients with eczema and psoriasis. British Journal of General Practice 2000; 50: 555-558.

47. Ayyalaraju R S, Finlay A Y. Inpatient Dermatology: United Kingdom and United States similarities. Chapter in Dermatologic Clinics: Inpatient Dermatology. Eds F A Kerdel, R S Kisner. W B Saunders Co, Philadelphia Dermatologic Clinics 2000; 18(3): 397-404

48. Al-Awadi R, Dykes P J, Gonzalez M, Finlay A Y Life activity impairment by skin disease. J Eur Acad Dermatol Venereol 2000; 14 (Suppl 1): 54.

49. Bissonnette R, Papp K A, Garovoy M, Walicke P, Watrous W. Hu 1124 improves dermatological-specific quality of life in subjects with moderate-severe psoriasis. J Eur Acad Dermatol Venereol 2000; 14 (Suppl 1): 255.

50. Finlay A Y Dermatology patients: what do they really need? Clin Exp Dermatol 2000; 25: 444-450

51. Marks R, Plunkett A, Merlin K, Jenner N. Atlas of Common Skin Diseases in Australia. University of Melbourne, Melbourne 2000 p9, 15, 19.

52. Mork C, Wahl A. Supervised climatotherapy improves quality of life and disease severity among patients with psoriasis. Quality of Life Research 2000; 9: Poster 43.

53. Harlow D, Poyner T, Finlay A Y, Dykes P J. Impaired quality of life in adults with skin disease in primary care. British Journal of Dermatology 2000; 143: 979-982.

54. Haynes M. Examining day-case and in-patient psoriasis care. Professional Nurse 2000; 16: 893-896.

55. Vensel E, Hilley T, Trent J, et al. Sustained improvement of the quality of life of patients with psoriasis after hospitalisation. J Am Acad Dermatol 2000; 43: 858-860.

56. Jobanputra R, Bachmann M. The effect of skin diseases on quality of life in patients from different social and ethnic groups in Cape Town, South Africa. International Journal of Dermatology 2000; 39: 826-831.

57. Halioua B, Beumont M G. Quality of life in dermatology. International Journal of Dermatology 2000; 39: 801-806

58. Thompson A K, Finn A F, Schoenwetter W F. Effect of 60 mg twice-daily Fexofenadine HCI on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. Journal of the American Academy of Dermatology 2000; 43: 24-30

59. Klassen A F, Newton J N, Mallon E. Measuring quality of life in people referred for specialist care of acne: comparing generic and disease-specific measures. Journal of the American Academy of Dermatology 2000; 43: 229-233.

60. Lundberg L, Johannesson M, Silverdahl M et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000; 80: 430-434.

61. Drake L, Prendergast M, Maher R et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001; 44: S65-S72.

62. Finlay A Y. Psoriasis from the patient's point of view. Arch Dermatol 2001; 137: 352-353

63. Von Der Werth J M, Jemee G B E. Morbidity in patients with hidradenitis urativa. Br J Dermatol 2001; 144: 809-813.

64. Ho V C Y, Griffiths C E M, Berth-Jones J et al. Intermittent short courses of cyclosporin microemulsion for the long-term management of psoriasis: a 2 year cohort study. J Am Acad Dermatol 2001; 44: 643-651.

65. Jemec BG B E, Kynemund L. Time spent on treatment in dermatology - how much time do outpatients use and is it a measure of morbidity? Acta Dermatoven APA 2001; 10:17-19

66. Touw C R, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten F F H, Finlay A Y. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001; 144: 967-972

67. Swartling C, Naver H, Lindberg M. Botulinum A toxin improves life quality in severe primary focal hyperhidrosis. Eur J Neurol 2001; 8: 247-52

68. Zaghloul S S, Cunliffe W J, Goodfield M J D. Compliance in psoriasis is highly correlated with psychological well-being. Br J Dermatol 2001; 145 (Suppl 59): 41.

69. Thomson K F, Pollock B, Sommer S, Wilkinson S M. The effect of patch testing on quality of life. Br J Dermatol 2001; 145 (Suppl 59): 19.

70. Williamson D, Gonzalez M, Finlay A Y. The effect of hair loss on quality of life. J Eur Acad of Dermatol & Venereol 2001; 15: 137-139.

71. Hahn BH, Melfi CA, Chuang T Y et al. Use of the Dermatology Life Quality Index (DLQI) in a Midwestern US Urban Clinic. J Am Acad Dermatol 2001; 45: 44-48.

72. Thomas K, Williams A, Avery A et al. Topical steroids in mild to moderate eczema - short burts of strong preparations or continuous use of minor ones? J Invest Dermatol 2001; 17: 758.

73. Christophers E, Bourcier M, Griffiths C, et al. Study design and demographics of a randomised, double-blind, placebo-controlled phase 3 dose-comparison study to evaluate weekly intramuscular administration of alefacept in chronic plaque psoriasis. JEADV 2001; 15 (Suppl 2): 249.

74. Ongenae K, De Schepper S, van Geel N et al. Impact of vitiligo on the quality of life in Belgium. JEADV 2001; 15 (Suppl 2): 232.

75. Kochergin, N G, Burova E P. Life quality assessment in psoriasis and atopic dermatitis. JEADV 2001; 15 (Suppl 2): 186.

76. Amir M, Vardy D, Narkiss T et al. Heliotherapy at the Dead Sea improves quality of life in psoriatic patients: a prospective study. Qual Life Research 2001; 10, 3: 236

77. Lvov AN, Ivanov OL, et al. Psychoneurological parameters and quality of life in patients with severe forms of atopic dermatitis. JEADV 2001; 15 (Suppl 2): 276

78. Williams T L, May C R, Esmail A, et al. Patient satisfaction with teledermatology is related to perceived quality of life. Br J Dermatol 2001; 145: 911-917.

79. Poli F, Dreno B, Vershoores M. An epidemiological study of acne in female adults: results of a survey conducted in France. JEADV 2001; 15: 541-545

80. Hutchings C V, Shum K W, Gawkrodger D J. Occupational contact dermatitis has an appreciable impact on quality of life. Contact Dermatitis 2001; 45(1): 17-20.

81. Schafer T, Staudt A, Ring J. German instrument for the assessment of quality of life in skin diseases (DIELH). Internal consistency, reliability, convergent and discriminant validity and responsiveness. Hautarzt 2001; 52(7): 624-628.

82. Swan M C, Paes T. Quality of life evaluation following endoscopic transthoracic sympathectomy for upper limb and facial hyperhydrosis. Ann Chir Gynaecol 2001; 90(3): 157-159.

83. Hiltscher D, Boslet W T, Fuchslocher M et al. Quality of life in patients with rosacea and rhinophyma. Akt Dermatol 2001; 27: 391-394

84. Thomson K F, Wilkinson S M, Sommer S, Pollock B. Eczema: quality of life by body site and the effect of patch testing. Br J Dermatol 2002; 146: 627-630.

85. Sivayathorn A. Quality of life assessment in psoriasis. Ann Dermatol Venereol 2002; 129: 1S12

86. Zollner TM, Paeslack I, Kaufmann R, Boehncke W H. Effectiveness and quality of life in patients with disfigurating skin disease applying decorative cosmetics. Ann Dermatol Venereol 2002; 129: 1S44.

87. Meurer M, Folster-Holst R, Brautigam M. Pimecrolimus (SDZ ASM 981) cream improves disease control and quality of life in the long-term management of atopic dermatitis in adults. Ann Dermatol Venereol 2002; 129: 1S47.

88. Etemesi BA. Quality of life in Tanzanian adults with chronic skin disease. Ann Dermatol Venereol 2002; 129: 1S253.

89. Diba VC, Loo WJ, Chawla M, Finlay AY. Dermatology Life Quality Index (DLQI) validation of an illustrated version. Ann Dermatol Venereol 2002; 129: 1S254-255.

90. Griffiths C, Langley R et al. Alefacept improves psoriasis and quality of life: Results of an international trial. Ann Dermatol Venereol 2002; 129: 1S280.

91. Gottlieb AB, Lowe NJ, Matheson RT, Lebsack ME. Efficacy of etanercept in patients with psoriasis. Ann Dermatol Venereol 2002; 129: 1S280.

92. Ertam I. Acne and quality of life: Is there a correlation between them in university students. Ann Dermatol Venereol 2002; 129: 1S374.

93. Campanati A, Guzzo T et al. How botulinum A toxin modifies life quality of patients suffering from focal severe hyperhidrosis. Ann Dermatol Venereol 2002; 129: 1S695.

94. Lowe N, Lebsack M Wande L. Psoriasis patients show improved quality of life when treated with Etanercept. Ann Dermatol Venereol 2002; 129: 1S762.

95. Papp K, Ellis C et al Alefacept improves psoriasis and quality of life: Results of a multiple-course trial. Ann Dermatol Venereol 2002; 129: 1S764.

96. Urbanowski S, Kosmowski. Quality of life, psychological condition, depression and alexithymia in patients with psoriasis vulgaris. Ann Dermatol Venereol 2002; 129: 1S798.

97. Zaghloul SS, Cunliffe WJ, Goodfield MJD. Compliance in acne is highly correlated to psychological well-being and self presentation. Br J Dermatol 2002; 147 (Suppl 62): 43.

98. Zaghloul SS, Goodfield MJD. Compliance in psoriasis: patients' self-reporting and factors affecting medication adherence. Br J Dermatol 2002; 147 (Suppl 62): 43-44.

99. Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002; 147 (Suppl 62): 50.

100. Nicolaou M, Swan MC, Paes T. Quality of life evaluation following endoscopic transthoracic sympathectomy for upper limb and facial hyperhidrosis. Br J Dermatol 2002; 147 (Suppl 62): 59.

101. Ammad S, Edwards C, Gonzalez M, Mills CM. The effect of blue light phototherapy on mild to moderate acne. Br J Dermatol 2002; 147 (Suppl 62): 95.

102. Mork C & Wahl A, Polit R N. Improved quality of life among patients with psoriasis after supervised climate therapy at the Canary Islands. J Am Acad Dermatol 2002; 47: 314-36.

103. Hermansen S E, Helland C A, Finlay A Y. Patients' and doctors' assessment of skin disease handicap. Clin & Exp Dermatol 2002; 27: 249-250.

104. Kiebert G, Sorensen S V, Revicki D, Fagan, S C, Doyle J J, Cohen J, Fivenson D. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol 2002; 41: 151-8.

105. Jayaprakasam A, Darvey A, Osborne G, McGibbon D. Comparisons of assessment of severity and quality of life in cutaneous disease. Clin Exp Dermatol 2002; 27: 306-8.

106. Gradwell C, Thomas K S, English J S, Williams H C. A randomised controlled trial of nurse follow-up clinics: do they help patients and free up consultants' time? Br J Dermatol 2002; 147: 513-517.

107. Hachem J P, DePaepe K, Sterckx G, Kaufman L, Rogiers V, Roseeuw D. Evaluation of key biographical and clinical parameters of skin barrier function among hospital workers. Contact Dermatitis 2002; 46: 220-223.

108. Kochergin N G, Samgin M A, Monakhow S A. Acne, adapalene and quality of life. JEADV 2002; 16 (Suppl 1): 116.

109. Griffiths C E M, Humbert P, Koo J, Ortonne J P, Christophers E. Relationship between clinical response and quality of life in psoriasis patients treated with alefacept. JEADV 2002; 16 (Suppl 1): 292.

110. Nicolaou M, Swan M C, Paes T. Endoscopic transthoracic sympathectomy: the effect on the quality of life of patients with facial, palmar and axillary hyperhidrosis and facial blushing. JEADV 2002; 16 (Suppl 1): 298.

111. Holme S A, Beattie P E, Fleming C J. Cosmetic camouflage advice improve quality of life. Br J Dermatol 2002; 147: 946-949.

112. Koo J, Menter A, Lebwohl M, Kozma C, Slaton T, Wojcik A Kowlaski J. The relationship between quality of life and disease severity: results from a large cohort of mild, moderate and severe psoriasis patients. Br J Dermatol 2002; 147: 1070-1071.

113. Mork C, Wahl A, Moum T. The Norwegian version of the Dermatology Life Quality Index: a study of validity and reliability in psoriatics. Acta Derm Venereol 2002; 82: 347-351.

114. Loo W-J, Lanigan S W. Laser treatment improves quality of life of hirsute females. Clin & Exp Dermatol 2002; 27(6): 439-441.

115. Fivenson D, Arnold R J G, Kaniecki D J, Cohen J L, Frech F, Finlay A Y. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organisation. J Managed Care Pharmacy 2002; 8(5): 333-342

116. Horn H M, Tidman M J. Quality of life in epidermolysis bullosa. Clin Exp Dermatol 2002; 27(8): 707-710.

117. Boehncke W H, Ochsendorf F, Paeslack I, Kaufmann R, Zollner T M. Decorative cosmetics improve the quality of life in patients with disfiguring skin diseases. Eur J Dermatol 2002; 12(6): 577-580.

118. Helbling I, Ferguson J E, McKenna M, Muston H L. Audit of admissions to dermatology beds in Greater Manchester. Clin & Exp Dermatol 2002; 27: 519-522.

119. Meurer M, Folster-Holst R, Wozel G, Weindinger G, Junger M, Brautigam M. Primecrolimus cream in the long-term management of atopic dermatitis in adults: A six-month study. Dermatology 2002; 205(3): 271-277.

120. McPherson T. Impact on the quality of life of lymphoedema patients following introduction of a hygiene and skin care regimen in a Guyanese community endemic for lymphatic filariasis: A preliminary clinical intervention study. Filaria Journal 2003; 2: 1

121. Parsad D, Pandhi R, Dogra S, Kanwar A J, Kumar B. Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome. Br J Dermatol 2003; 148; 2: 373-374.

122. Loo W-J, Diba V, Chawla M, Finlay A Y. Dermatology Life Quality Index: influence of an illustrated version. Br J Dermatol 2003; 148: 279-284.

123. Ellis C N, Mordin M M Adler E Y. Effects of Alefacept on health-related quality of life in patients with psoriasis: Results from a randomised, placebo controlled phase II trial. Am J Clin Dermatol 2003; 4(2): 131-139.

124. Gollnick H, Cunliffe W. Report from a Global Alliance to Improve Outcomes in Acne. JAAD 2003; 49: S32.

125. Berger K, Kugland B, Khlken B, Augustin M. Cost of chronic plaque psoriasis in Germany: an analysis from the patients and payer perspectives. JEADV 2003; 17 (Suppl 1): 36.

126. Taieb C, Nocera T, Verriere F, Myon E. Psoriasis and atopic dermatitis: cross-description of patients' quality of life. JEADV 2003; 17 (Suppl 1): 38.

127. Humbert Ph, Bassas-Bresca S, van der Valk P, Merot F, Ermosilla S V, Boyer J F, Mengeaud J V. Interest of an emollient combination of two hygiene products and a cream containing Oat Rhealba ® extract in atopic dermatitis. JEADV 2003; 17 (Suppl 1): 50.

128. Öztap M O, Öztap P, Aslan S, Adypen H, Önder M. Comparison of the effects of PUVA and non PUVA treatment on the quality of life of patients with psoriasis vulgaris: a non-randomized, cross-sectional study. JEADV 2003; 17 (Suppl 1): 59.

129. Finlay A Y, Myon E, Taieb C. Immoderate exposure to the sun: short-term impact on quality of life. JEADV 2003; 17 (Suppl 1):62.

130. Campanati A, Penna L, Guzzo T, Menotta L, Silvestri B, Lagalla G, Gesuita R, Offidani. Quality of life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin: results of an open-label study. Clin Ther 2003; 25: 298-308.

131. Reilly M C, Lavin P T, Kahler K H, Pariser D M. Validation of the Dermatology Life Quality Index and the Work Productivity and Activity Impairment - Chronic Hand Dermatitis questionnaire in chronic hand dermatitis. J Am Acad Dermatol 2003; 48: 128-130.

132. Pittler M H, Armstrong N C, Cox A, Collier P M, Hart A & Ernst E. Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis. Br J Dermatol 2003; 148(2): 307-313.

133. Holme S A, Edwards C, Hughes M T, Stone N M. Dermatology quality of life during contact dermatitis patch testing investigations. Br J Dermatol 2003; 148: 847.

134. Chan J J, Gebeuer K. Treatment of severe recalcitrant plaque psoriasis with single-dose intravenous tumour necrosis factor-alpha antibody (infliximab). Australas J Dermatol 2003; 44(2): 116-20.

135. Finlay A Y, Salek M S, Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 2003; 206(4): 307-315.

136. Charman C. Chambers C, Williams H. Measuring atopic dermatitis severity in randomized controlled clinical trails: What exactly are we measuring? J Invest Dermatol 2003; 120 (6): 932-941.

137. Finlay A Y. The impact of acne on quality of life. J Am Acad Dermatol 2003; 49: 133-135.

138. Sterodimas A, Nicolaou M, Paes T R F. Botulinum toxin A injection for forehead hyperhidrosis: a quality of life study. Br J Dermatol 2003; 149 (Suppl 64): 107.

139. Kirkup M E, Spicer J K, Rumsey N J, Kennedy C T C. Quality of life in older adults with skin disorders. Br J Dermatol 2003; 149 (Suppl 64): 35.

140. McPherson T, Penzer. A comparison of quality of life and disease severity in 54 patients with lymphoedema in Guyana. Br J Dermatol 2003; 149 (Suppl 64): 34.

141. Etemesi B A. Impact of chronic skin disease on the quality of life of Tanzanian adults. Br J Dermatol 2003; 149 (Suppl l 64): 31-32.

142. Lowe N, Yamauchi P, Zitnik R. Efficacy and safety of Enbrel® (etanercept) in patients with psoriasis: results of a phase III study. Br J Dermatol 2003; 149 (Suppl 64): 20.

143. Wong C S M, Sewell M, Yell J. Nurse practitioners compare favourably with doctors in the treatment of eczema and psoriasis. Br J Dermatol 2003; 149 (Suppl 64): 4-5.

144. Woo P N, Hay I C, Ormerod A D. An audit of the value of patch testing and its effect on quality of life. Contact Dermatitis 2003; 48: 244-247.

145. McKenna S P, Cook S A, Whalley D, Doward L C, Richards H L, Griffiths C E M, Van Assch D. Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol 2003; 149(2): 323-331.

146. Mazzotti E, Picardi A, Sampogna F, Sera F, Pasqunini P, Abeni D,. The Idi multipurpose psoriasis research on vital experiences (improve) study group. Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis. Br J Dermatol 2003 149(2): 318-322.

147. Ayyalaraju R S, Finlay A Y, Dykes P J, Trent J T, Kirsner R S, Kerdel F A. Hospitalization for severe skin disease improves quality of life in the United Kingdom and the United States: A comparative study. JAAD 2003; 49: 249-254.

148. Schmid-ott G, Burchard R, Niederauer H H, Lamprecht F,Kunsebeck H W. Stigmatization and quality of life of patients with psoriasis and atopic dermatitis. Hautarzt 2003; 54(9): 852-857.

149. Balkrishnan R, McMichael A J, Camacho F T, Saltzberg F, Housman Grummer S, Feldman S R, Chren M M. Development and validation of a health-related quality of life instrument for women with melasma. Br J Dermatol 2003; 149(3): 572-577.

150. Fleckman P, Hamill G, Weinstock M A. The National Registry for Ichthyosis and Related disorders - health related quality of life and patient reported outcomes. J Invest Dermatol 2003; 121(1): 0420.

151. Carlin C S, Feldman S R, Krueger J G, Menter A Krueger C G. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint. J Invest Dermatol 2003; 121(1): 0393.

152. Callis K P, Carlin C S, Krueger C G. Correlation of National Psoriasis Foundation score components with quality of life measures in psoriasis. J Invest Dermatol 2003; 121(1): 0357.

153. Skoet R, Zachariae R, Agner T. Contact dermatitis and quality of life: a structured review of the literature. Br J Dermatol 2003; 149: 452-456.

154. Weisman S, Pollack C R, Gottschalk R W. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatol Treatment 2003; 14: 158-165.

155. Sterry W. Psoriasis - impact on QoL - efalizumab positive outcomes. JEADV 2003; 17 (Suppl 3) 439.

156. Holloway V, Feldman S. Corrective cosmetics improve the quality of life in patients with disfiguring disease. JEADV 2003; 17 (Suppl 3): 427.

157. Chaidemenos C, Avgoustinaki N, Karakatsanis,G, Chatzistylianos,M, Papakonstantinou M, Mourellou O. Effect of intermittent and continuous cyclosporin therapy on the clinical and quality of life parameters of psoriasis. JEADV 2003; 17 (Suppl 3): 381.

158. Carey W, Gulliver W P. Efalizumab therapy improves and sustains health-related quality of life in patients with moderate to severe plaque psoriasis. JEADV 2003; 17 (Suppl 3) 371.

159. Ouellet J P, Toth D, Gratton D. Efalizumab provides rapid onset of clinical benefit in patients with moderate to severe plaque psoriasis. JEADV 2003; 17 (Suppl 3) 371.

160. Taieb C, Verriere F, Nocera T, Myon E. Psoriasis and atopic dermatitis: cross-description of patients' quality of life. JEADV 2003; 17 (Suppl 3): 366.

161. Dierckxsen L, Ongenae K, van Geel N, Naeyaert J. Vitiligo: profile of a Belgian cohort. JEADV 2003; 17 (Suppl 3) 359.

162. Dierckxsen L, Ongenae K, van Geel N, Naeyaert J. Vitiligo and quality of life: impact of complexion corrector. JEADV 2003; 17 (Suppl 3): 358.

163. Kochergin N G, Yutanova N S. Mometasone furoate 0.1% with salicylic acid 5% ointment in psoriasis and atopic dermatitis. JEADV 2003; 17 (Suppl 3): 350.

164. Holm E A, Jemec G B E. Why is assessment of health-related quality of life so important? JEADV 2003; 17 (Suppl 3): 304.

165. Taieb C, Verriere F, Nocera T, Myon. Impact of hydrotherapy cares on the quality of life of patients suffering from skin disease. JEADV 2003; 17 (Suppl 3): 273.

166. Feldman S R, McMichael A, Balkrishnan R, Rapp S R, Crambes O, Abella M L, Bouloc A. The effect of corrective cosmetics on quality of life of patients with facial disfigurements. JEADV 2003; 17 (Suppl 3) 202.

167. Humbert Ph, Basses-Bresca S, van der Valk P, Mengeaud V, Ermosilla V, Boyer F, Merot F. Interest of an emollient combination of two hygiene products and a cream containing Oak Rhealba ® extract in atopic dermatitis. JEADV 200317 (Suppl 3): 174.

168. Samgin M A, Monakhov S A. Adapalene gel 0.1% in the treatment of acne in Moscow. JEADV 2003; 17 (Suppl 3): 166.

169. Calikoglu E, Oztas P, Cetin P. The evaluation of psychiatric tests in seborrhoeic dermatitis patients. JEADV 2003; 17 (Suppl 3): 159.

170. Caro I, Woolley J M, Zitnik R J. Effects of etanercept therapy on health-related quality of life of subjects with moderate to severe psoriasis. JEADV 2003; 17 (Suppl 3): 140.

171. Caro I, Leonardi C, Gottlieb A B, Zitnik R J. Efficacy and safety of ENBREL® (Etanercept) in patients with psoriasis: results of a 24-week US phase III study. JEADV 2003; 17 (Suppl 3): 140.

172. Langley R. An improvement of 50% or more in psoriasis area severity index (PASI) represents substantial improvement for patients treated with alefacept. JEADV 2003; 17 (Suppl 3): 139.

173. Papp K Zitnik R. Efficacy and safety of ENBREL® (Etanercept) in patients with psoriasis: results of a global 12-week phase III study. JEADV 2003; 17 (Suppl 3): 139.

174. Christopher E, Vanishnaw AK. A broad spectrum of patients with psoriasis benefit from alefacept therapy. JEADV 2003; 17 (Suppl 3): 138.

175. Lewis V, Statham B, Chowdhury M. How does the diagnosis of latex allergy affect people's lives? JEADV 2003; 17 (Suppl 3): 124.

176. Hongbo Y, Harrison M A, Salek M S, Finlay A Y. Assessing the meaningfulness of Dermatology Life Quality Index (DLQI) scores. JEADV 2003; 17 (Suppl 3): 113.

177. Finlay A Y. Quality of life in dermatology - introduction to workshop. JEADV 2003; 17 (Suppl 3): 58.

178. Finlay A Y. What do quality of life scores really mean? JEADV 2003; 17 (Suppl 3): 58.

179. Shikiar R, Bresnahan B W, Stone S P, Thompson C, Koo J, Revicki D A, Validity and reliability of patient reported outcomes used in psoriasis: results of two randomised clinical trials. Health Qual Life Outcomes 2003; 1(1): 53.

180. Bergstrom K G, Arambula K, Kimball A B. Medication formulation affects quality of life: randomized single-blind study clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.0.5% for the treatment of psoriasis. Cutis 2003; 72(5): 407-411.

181. Hongbo Y, Harrison M A, Salek S S, Finlay A Y. What do the Dermatology Life Quality Index (DLQI) scores really mean in terms of patients' over all quality of life? Quality of Life Research 2003; 12: 778.

182. Segard C, Verriere F, Nocera T, Myon E Taieb C. Impact of hydrotherapy care on the quality of life of patients' suffering from skin disease. Quality of Life Research 2003; 12: 777.

183. Gordon K B, Papp K A, Hamilton T K, Walicke P A, Dummer W, Li N, Bresnanhan B W, Menter A. Efalizumab for patients with moderate to severe plaque psoriasis: a random controlled trial. JAMA 2003; 290(23): 3073-3080.

184. Gottlieb A B, Matheson R T, Low N, Krueger G G, Kang S, Goffe B S, Gaspari A A, Ling M, Weinstein G D, Nayak A, Gordon K B, Zitnik R. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-1632.

185. Leonardi C L, Powers J L, Matheson R T, Goffe B S, Zitnik R, Wang A, Gottlieb A B, for the Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. New England J of Med 2003; 349 21: 2014-2022.

186. Krueger G G, Callis K P. Development and use of alefacept to treat psoriasis. Am Acad Dermatol 2003; 49 (2): S87-S97.

187. Leonardi C L. Efalizumab: An overview. Am Acad Dermatol 2003; 49 (2): S98-S104.

188. Goffe B, Cather J C. Etanercept: An overview. Am Acad Dermatol 2003; 49 (2): S105-S111.

189. Littenberg B, Partilo S, Licata A, Kattan M W. Paper Standard Gamble: the reliability of a paper questionnaire to assess utility. Med Decis Making 2003; 23(6): 480-488.

190. Mork C, Ozek M, Wahl A K. Treatment or leisure? Climate therapy of patients with psoriasis and psoriatic arthritis. Tidsskr Nor Laegeforen 2004; 124(1): 60-62.

191. Won C, Seo P, Park Y, Yang J, Lee K, Sung K, Park C, Kim D, Char Won Y, Kim K. A Multicentre trial of the efficacy and safety of 0.03% tacrolimus ointment for atopic dermatitis in Korea. J Dermatolog Treat 2004; 15(1): 30-34.

192. Jenner N, Campbell J, Marks R. Morbidity and cost of atopic eczema in Australia. Australas J Dermatol 2004; 45(1): 16-22.

193. Ganemo A, Sjoden P O, Johansson E, Vahlquist A, Lindbert M. Health-related quality of life among patients with ichthyosis. Eur J Dermatol 2004; 14(1): 61-66.

194. Menter A, Kosinski M, Bresnahan B W, Papp K A, Ware J E Jr. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trails of moderate to severe plaque psoriasis. J Drugs Dermatol 2004; 3(1): 27-38.

195. Feldman S R, Bala M, Menter A, Gordon K B. The quality of life of patients with severe psoriasis treated with infliximab. J Am Acad Dermatol 2004; 50 (3): P2.

196. Gordon K B, Korman N, Frankel E, Zitnik R. Efficacy of etanercept in an integrated multi-study database of patients with psoriasis. J Am Acad Dermatol 2004; 50 (3): P2.

197. Jacobi A, Schuler G, Hertl M. Long-term efficacy and safety of TNF-alpha-inhibitor infliximab in severe atopic dermatitis. J Am Acad Dermatol 2004; 50 (3): P3.

198. Spalding J R, Kowalski J, Lee J, Glaser D A. Effect of pharmacologic treatment on dermatologic-specific quality of life (QoL): A comparison of botulinum toxin type-A (BT-A) for primary focal hyperhidrosis (HH) to medical treatments for other dermatological diseases. J Am Acad Dermatol 2004; 50 (3): P51.

199. Kowalski J W, Eadie N, Dagget S, Lai P-Y. Validity and reliability of the Hyperhidrosis Disease Severity Scale (HDSS). J Am Acad Dermatol 2004; 50 (3): P51.

200. Lewis V J, Statham B, Chowdhury M. How does the diagnosis of latex allergy affect peoples' lives? J Am Acad Dermatol 2004; 50 (3): P66.

201. McMichael A J, Balkrishnan R, Bouloc A, Feldman S. Impact of corrective cosmetic use on health-related quality of life in women with severe facial pigmentary disorders. J Am Acad Dermatol 2004; 50 (3): P78.

202. Strober B E, Yamauchi P, Korman N, Stevens S. Efficacy of etanercept in psoriatic patients previously treated with systemic therapy or phototherapy. J Am Acad Dermatol 2004; 50 (3): P147.

203. Feldman S R, Kimball A, Woolley M J, Zitnik R. Clinically meaningful improvements in health-related quality of life from etanercept therapy for patients with moderate to severe psoriasis. J Am Acad Dermatol 2004; 50 (3): P155.

204. Krueger G G, Woolley M J, Zitnik R. The effects of etanercept therapy on patient reported outcomes for patients with moderate to severe psoriasis. J Am Acad Dermatol 2004; 50 (3): P155.

205. Kimball A, Krueger G, Woolley M J. The Dermatology Life Quality Index (DLQI) provides qualitatively different information from the PSAI. J Am Acad Dermatol 2004; 50 (3): P156.

206. Menter A, Hamilton T, Caro I, Chen-Rundle A. Impact of efalizumab on patient-reported outcomes in patients with moderate to severe plaque psoriasis: Pooled results from three randomized phase III trials. J Am Acad Dermatol 2004; 50 (3): P156.

207. Stone S, Papp K, Caro I, Bresnahan B. Interpretation of positive patient response to efalizumab for the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol 2004; 50 (3): P157.

208. Elewski B E, Boh E, Papp K, Zitnik R. Efficacy and safety of etanercept in patients with psoriasis: Results of a global phase III study. J Am Acad Dermatol 2004; 50 (3): P159.

209. Whalley D, McKenna S P, Dewar A L. Erdman R A, Kohlmann T, Niero M, Cook S A, Crickx B, Herdman M J, Frech F, Assche D Van. A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD). BJD 2004; 150: 274-283.

210. Feldman S R, Menter A Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. BJD 2004; 150: 317-326.

211. Lewis V L, Finlay A Y. Ten years experience of the Dermatology Life Quality Index (DLQI) J Investig Dermatol Symp Proc 2004; 9(2):169-180.

212. Rhee J S, Matthews B A, Neuburg M, Smith T L, Burzynski M, Nattinger A B. Skin cancer and quality of life: assessment with the Dermatology Life Quality Index. Dermatol Surg 2004; 30(4): 525-9.

213. de Korte J, Sprangers M A G, Mombers F M C, Bos J D. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004; 9(2):140-147.

214. Strober B, Yamauchi P, Korman N, Xia H, Stevens S. The efficacy of etanercept in psoriasis patients with varying treatment histories. JID 2004; 122: A43.

215. Feldman S, Kimball A, Woolley J, Zitnik R. Etanercept treatment leads to rapid and sustained improvements in the quality of life of patients with moderate to severe psoriasis. JID 2004; 122: A55.

216. Krueger G, Woolley J, Zitnik R. Clinically meaningful improvements in patient-reported outcomes for patients with moderate to severe psoriasis receiving etanercept. JID 2004; 122: A55.

217. Sampognoa F, Sera F, Abeni D; IDI Multipurpose psoriasis research on vital experience (IMPROVE) investigators. Measure of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004; 122 (3): 602-607.

218. Uttjek M, Dufaker M, Nygren L, Stenberg B. Determinants of quality of life in a psoriasis population in northern Sweden. Acta Derm Venereol 2004; 84(1): 37-43.

219. van der Ham R, Shumack S, Duru G, Beresniak A. Effects of efalizumab on health-related quality-of-life outcomes: an international phase III randomized, controlled trial of patients with moderate to severe chronic plaque psoriasis. JEADV 2004; 18 (Suppl 1): 103.

220. Spalding J, Hamm H, Naumann M, Lee J T, Kowalski J W. Literature review and comparison of the dermatology-specific quality of life effect of primary focal hyperhidrosis and improvement following treatment with botulinum toxin type-A (BTX-A) JEADV 2004; 18 (Suppl 1): 97.

221. Rustin M, on behalf of the UK Tacrolimus Ointment Study Group. Pharmacoeconomics of 0.1% ointment in adults and children with moderate to severe atopic dermatitis. JEADV 2004; 18 (Suppl 1): 90.

222. Reitamo S, on behalf of the UK Tacrolimus Ointment Study Group. Quality of life improved in adults with moderate to severe atopic dermatitis treated with 0.1% tacrolimus ointment. JEADV 2004; 18 (Suppl 1): 88.

223. Randazzo B, Prens E P, Rustin M. Patient-reported outcomes improve significantly in psoriasis patients receiving etanercept therapy. JEADV 2004; 18 (Suppl 1): 87.

224. Randazzo B, Griffiths C E M, Dubrett L, Meurer M. Etanercept monotherapy is safe and efficacious in patients with psoriasis: results of a worldwide phase III study. JEADV 2004; 18 (Suppl 1): 87.

225. Randazzo B, van der Kerkhof P C M, Sterry W, Ortonne J-P, Berth-Jones J. Efficacy of etanercept in patients with psoriasis: results of an integrated multi-study analysis. JEADV 2004; 18 (Suppl 1):86.

226. Nash P, Thaci D, on behalf of the TOPAS Study Group. The impact of Leflunomide on skin symptoms in patients with psoriasis and psoriatic arthritis. JEADV 2004; 18 (Suppl 1): 78.

227. Myon E, Dubertret L, Nocera T, Latapie J P, Taieb C. Sunburns and quality of life. JEADV 2004; 18 (Suppl 1): 77.

228. Myon E, Dubertret L, Nocera T, Latapie J P, Taieb C. Sunburns and activity. JEADV 2004; 18 (Suppl 1): 76.

229. Carey W, Menter A, Gilbert M, Gatton D, Rosoph L, Shear N, Langley R. The effects of 24 weeks of continuous efalizumab therapy on health-related quality of life in patients with moderate to severe chronic plaque psoriasis. JEADV 2004; 18 (Suppl 1): 49.

230. Meding B, Wallenhammar L-M, Lindberg M, Nyfjall M. Health-related quality of life and hand eczema. Contact Dermatitis 2004; 50(3): 152-153.

231. Zachariae R, Zachariae C, Ibsen H H, Mortensen J T, Wulf H C. Psychological symptoms and quality of life of dermatology outpatients and hospitalized dermatology patients. Acta Derm Venereol 2004; 84: 205-212.

232. Blanch J, Rousaud A, Martinez E, De Lazzari E, Milinkovic A, Peri J M, Blanco J L, Jaen J, Navarro V, Massana G, Gatell J M. Factors associated with severe impact of lipodystrophy on the quality of life of paints infected with HIV-1. Clin Infect Dis 2004; 38(10): 1464-1470.

233. Wallenhammar L M, Nyfjall M, Lindberg M, Meding B. Health-related quality of life and hand eczema - a comparison of two instruments, including factor analysis. J Invest Dermatol 2004; 122(6): 1381-1389.

234. Yazici K, Baz K, Yazici A, Kokturk A, Tot S, Demirserent D, Butural Disease-specific quality of life is associated with anxiety and depression in patients with acne. J Eur Acad Dermatol Veneroel 2004; 18(4): 435-439.

235. Lewis V J, Chowdhury M M U, Statham B N. Natural rubber latex allergy: impact on lifestyle and quality of life. BJD 2004; 151; (Suppl 68): 113.

236. Ling T C, Richards H L, Brownrigg M, Huber K, Brooke R C C, Gibbs N K, Rhodes L R. Psychological distress in polymorphic light eruption. BJD 2004; 151; (Suppl 68): 104.

237. Woo P N, White M I. A family study of erythrokeratoderma variabilis. BJD 2004; 151; (Suppl 68): 71.

238. Sladden M J, Mortimer N J, Hutchinson P E. Severe, refractory, chronic plaque psoriasis successfully treated with adalimumab (Humira ®). BJD 2004; 151; (Suppl 68): 55.

239. Chew A-L, Bennett A, Smith C H, Barker J, Kirkham B. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. BJD 2004; 151; (Suppl 68): 55.

240. Zaghloul S S, Goodfield M J D. Objective assessment of compliance with different topical therapies in psoriasis. BJD 2004; 151; (Suppl 68): 52.

241. Zaghloul S S, Goodfield M J D. The influence of nurse education clinics as a supplementary technique on compliance in psoriasis. BJD 2004; 151; (Suppl 68): 51.

242. Helbling I, Ale S, Anda G de. Use of the validated Spanish version of the Dermatology Life Quality Index questionnaire in Uruguay. BJD 2004; 151; (Suppl 68): 46.

243. Hongbo Y, Thomas C L. Harrrison M A, Salek M S, Finlay A Y. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? BJD 2004; 151; (Suppl 68): 46.

244. Wain E M, Ronda L, Barker J N W N, Smith C H. Prospective, open, nonrandomized study investigating efficacy and safety of fumaric acid esters in a cohort of patients with severe, recalcitrant, chronic plaque psoriasis. BJD 2004; 151; (Suppl 68): 6.

245. Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer P J, Schneider D, Weidinger G, Braeutigam M. Long-term efficacy and safety of pimcrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004; 208: 365-372.

246. Zaghloul S S, Goodfield M J D. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004; 140: 408-414.

247. Yazici K, Baz K, Kokturk A,, Tot S, Demirseren D, Buturak V. Disease -specific quality of life is associated with anziety and depression in patients with acne. JEADV 2004; 18: 435-439.

248. Wallenhammar L-M, Nyfjall M, Lindberg M, Meding B. Health-related quality of life and hand eczema - A comparison of two instruments, including factor analysis. JID 2004; 122(6): 1381-1387.

249. Szepietowski,J, Salomon J,, Finlay A T, Klepacki A, chodynicka B, Marionneau N, Taieb C, Myon E. DLQI: Polish version. Dermatlogia Kliniczna 2004; 6(2): 63-70.

250. Charman C R, Venn A J, Williams H C. The patient-orientated eczema measure - development and validation of anew tool for measuring atopic eczema severity from the patients' perspective. Pead Dermatol 2004; 21 (3): 337.

251. Augustin M, Wenninger K, Amon U, Schroth M J, Kuster W. Chren M, Kupfer J, Gieler U. German adaptation of the Skindex-29 questionnaire on quality of life in dermatology: Validation and clinical results. Dermatology 2004; 209: 14-20.

252. Katugampola R P, Hongbo Y, Finlay A Y. The relationship between patient-rated quality of life and clinicians' management decisions in psoriasis - A prospective study. J Invest Dermatol 2004; 123 (2): A70.

253. Singh A, Ganguly R, Sato R. Clinically meaningful improvement in Dermatology Life Quality Index in patients with chronic plaque psoriasis: A meta-analytic summary of randomized clinical trials of Etanercept. J Invest Dermatol 2004; 123 (2): A69.

254. van der Kerkhof P C M, Sterry W, Ortonne J-P, Randazzo B, Singh A, Ganguly R, Wang H. Etanercept improves quality of life of patients with chronic plaque psoriasis: a meta-analytic summary of randomized clinical trials of Etanercept. J Invest Dermatol 2004; 123 (2): A69.

255. Griffiths C E M, Sterry W, Henninger E. Safe psoriasis control: Evaluation of a new approach to assessing efficacy of psoriasis treatments. J Invest Dermatol 2004; 123 (2): A68.

256. Suchan M, Jenisch S, Budahl R, Christophers E, Weichenthal M. Objective severity measures and quality of life in patients with psoriasis. J Invest Dermatol 2004; 123 (2): A67.

257. Ortonne J-P, Sterry W, Shear N, Shumack S, Duru G, Beresniak A. Impact of Efalizumab on health-related quality of life outcomes in patients with moderate to severe chronic plaque psoriasis: Results of the international randomized controlled phase II clinical experience acquired with Raptiva (CLEAR) trial. J Invest Dermatol 2004; 123 (2): A67.

258. van der Kerkhof P C M, Sterry W, Ortonne J-P, Berth-Jones J, Randazzo B. Etanercept efficacy results from an integrated multi-study in patients with psoriasis. J Invest Dermatol 2004; 123 (2): A65.

259. Gottlieb A B, Gordon K, Gaspari A A, Randazzo B. Clinical and pathologic improvements in patients with psoriasis following Etanercept monotherapy. J Invest Dermatol 2004; 123 (2): A65.

260. Aghaei s, Sodaifi M, Jafari P, Mazharinia N, Finlay A Y. DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatol 2005; 4(1): 8.

261. Lennox R D, Leahy M J. Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life. Ann Allergy Asthma Immunol 2004; 93(2): 142-146.

262. Holm E A, Esmann S, Jemec G B E. Does visible atopic dermatitis affect quality of life more in women than in men? Gender Medicine 2004; 1(2): (in press)